Education
About Us
Working with TipRanks
Follow Us
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Total Valuation
Kalaris Therapeutics has a market cap or net worth of $168.38M. The enterprise value is $32.64M.
Market Cap$168.38M
Enterprise Value$32.64M
Share Statistics
Kalaris Therapeutics has 18,702,417 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,702,417
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kalaris Therapeutics’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -48.77%.
Return on Equity (ROE)-0.52
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-48.77%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-4.20M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kalaris Therapeutics is ―. Kalaris Therapeutics’s PEG ratio is -0.13.
PE Ratio―
PS Ratio0.00
PB Ratio0.40
Price to Fair Value0.40
Price to FCF-0.67
Price to Operating Cash Flow-3.07
PEG Ratio-0.13
Income Statement
In the last 12 months, Kalaris Therapeutics had revenue of 0.00 and earned -58.77M in profits. Earnings per share was -11.73.
Revenue0.00
Gross Profit0.00
Operating Income-55.26M
Pretax Income-58.77M
Net Income-58.77M
EBITDA-58.77M
Earnings Per Share (EPS)-11.73
Cash Flow
In the last 12 months, operating cash flow was -33.66M and capital expenditures -183.00K, giving a free cash flow of -33.84M billion.
Operating Cash Flow-33.66M
Free Cash Flow-33.84M
Free Cash Flow per Share-1.81
Dividends & Yields
Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.43
52-Week Price Change-11.46%
50-Day Moving Average6.17
200-Day Moving Average5.01
Relative Strength Index (RSI)65.28
Average Volume (3m)136.22K
Important Dates
Kalaris Therapeutics upcoming earnings date is Nov 12, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
Kalaris Therapeutics as a current ratio of 22.63, with Debt / Equity ratio of 3.69%
Current Ratio22.63
Quick Ratio22.63
Debt to Market Cap0.00
Net Debt to EBITDA2.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kalaris Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kalaris Therapeutics EV to EBITDA ratio is 1.24, with an EV/FCF ratio of 1.07.
EV to Sales0.00
EV to EBITDA1.24
EV to Free Cash Flow1.07
EV to Operating Cash Flow1.07
Balance Sheet
Kalaris Therapeutics has $77.00M in cash and marketable securities with $1.54M in debt, giving a net cash position of $75.45M billion.
Cash & Marketable Securities$77.00M
Total Debt$1.54M
Net Cash$75.45M
Net Cash Per Share$4.03
Tangible Book Value Per Share$22.62
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kalaris Therapeutics is $16.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.67
Price Target Upside65.71% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast63.31%